Leerink Swann Upgrades MAP Pharmaceuticals (MAPP) to Outperform
More News related to MAPP
- MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
- MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
- 'Headache' Publication Describes Potential Mechanistic Rationale for LEVADEX(TM) Favorable Adverse Event Profile
- MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
- MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
Leerink Swann upgrades MAP Pharmaceuticals (Nasdaq: MAPP) from Market Perform to Outperform.
To see more analyst ratings on MAPP Click Here.
MAP Pharmaceuticals, Inc. uses inhalation technologies to improve the therapeutic benefits and commercial attractiveness of drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Related Categories
UpgradesStocks Mentioned
+0.20Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
